Archive for May 2026

AUSTIN, TX / ACCESS Newswire / April 23, 2026 / Aspira Women’s Health Inc. (“Aspira”) (OTCQB:AWHL), an AI-enhanced bio-analytics company focused on the development of noninvasive gynecologic disease diagnostics and disease management tools, today announced it is completing the buildout of its molecular laboratory in Q2 2026, marking a major operational milestone that accelerates development and future commercialization…

AUSTIN, TX / ACCESS Newswire / November 14, 2025 / Aspira Women’s Health Inc. (“Aspira”) (OTCQX:AWHL), an AI enhanced bio-analytics based women’s health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and nine-month periods ended September 30, 2025. September Q3 Highlights: Aspira reported relatively…

Aspira Executes New, Scalable Laboratory Services Agreement in One of the Largest Markets in the US AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / October 29, 2025 / Aspira Women’s Health Inc., abio-analytical-based women’s health company focused on gynecologic disease diagnostics, today announced it has executed a new laboratory services agreement with University of Texas Medical Branch…

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Aspira Women’s Health Inc. (OTCQX: AWHL), an AI enhanced bio-analytical based women’s health company, has qualified to trade on the OTCQX® Best Market. Aspira Women’s Health Inc. upgraded to OTCQX from the…